1. Home
  2. AFL vs REGN Comparison

AFL vs REGN Comparison

Compare AFL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AFLAC Incorporated

AFL

AFLAC Incorporated

HOLD

Current Price

$115.23

Market Cap

60.9B

Sector

Finance

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$801.82

Market Cap

68.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AFL
REGN
Founded
1955
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.9B
68.8B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
AFL
REGN
Price
$115.23
$801.82
Analyst Decision
Hold
Buy
Analyst Count
11
25
Target Price
$110.18
$830.16
AVG Volume (30 Days)
1.9M
514.7K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
2.10%
0.55%
EPS Growth
N/A
8.19
EPS
3.61
18.95
Revenue
$17,164,000,000.00
$5,872,227,000.00
Revenue This Year
N/A
$12.45
Revenue Next Year
$1.69
$10.13
P/E Ratio
$31.75
$42.42
Revenue Growth
N/A
20.82
52 Week Low
$105.43
$541.00
52 Week High
$130.22
$859.34

Technical Indicators

Market Signals
Indicator
AFL
REGN
Relative Strength Index (RSI) N/A 54.51
Support Level N/A $732.04
Resistance Level N/A $818.06
Average True Range (ATR) 0.00 16.31
MACD 0.00 -3.25
Stochastic Oscillator 0.00 40.51

Price Performance

Historical Comparison
AFL
REGN

About AFL AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments: Aflac Japan, which generates the maximum revenue, and Aflac U.S.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: